22.08.2025

Egnach, August 22, 2025 – Resaphene Suisse AG announces that tinniwell® not only achieves proven results in tinnitus treatment but also shows promising results in migraine therapy. Initial clinical observations indicate: Patients who start using tinniwell® 30 to 60 minutes before a migraine aura either completely avoid the attack or experience it in a significantly milder form.

Migraine: a global health problem

• About 14% of the world’s population suffers from migraines (WHO, 2023).

• Women between the ages of 20 and 50 are particularly affected – a group that has often been inadequately treated.

• In Germany, over 8 million people are affected, and in Switzerland, more than 1 million.

Mechanism of action scientifically plausible

The combination of heat application, muscular relaxation, and targeted neurostimulation through audio frequencies acts on the same neural circuits that are involved in both tinnitus and migraines. Early application just before or during the aura phase can raise the pain threshold and modulate vasodilation in the brain.

Next steps: clinical validation

Resaphene plans a multicenter study in 2026 with leading headache centers in Germany and Switzerland to systematically confirm the results. The goal is to establish tinniwell® as the first non-drug, multimodal home therapy for migraines.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Egnach, Switzerland, is a medical technology company founded in 2015, and since 2016, it has been selling a tinnitus therapy device under the name tinniwell.

++ Contact for inquiries:

Resaphene Suisse AG

Ms. Anke Rauterkus (Chief Executive Officer)
Bahnhofplatz 5
9322 Egnach
Switzerland
T. +41 71 510 07 24
a.rauterkus@resaphene.ch